To the Editor.
—Bronchial asthma, as noted in the May Archives article, "Some Recent Advances in the Management of Asthma" (1982;142:933-935), afflicts a sizable number of people in the United States and is a common cause of lost man-hours from school and work. Therefore, I would suggest that the omission of a significantly beneficial form of therapy be called to the attention of your readers.The value of hyposensitization therapy in ameliorating asthma symptoms in selected patients who have extrinsic allergic asthma has been noted by clinicians and patients since 1911, when Noon1 first reported on the subject. Recent attempts to explain the basic immunologic mechanisms involved have led to much laboratory research in hyposensitization. One such effort culminated recently in an article by Hsieh.2 The studies cited in this article clearly demonstrate the effectiveness of hyposensitization therapy in treating allergic asthma and show that such immunotherapy is